Latest Breaking News On - Progressive familial intrahepatic cholestasis - Page 1 : vimarsana.com

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesIntrahepatic cholestasisChris peetzEuropean commissionCommittee for orphan medicinal productsDrug administrationMirum pharmaceuticals incHealth canadaMirum pharmaceuticalsEuropean committeeMedicinal productsHuman useProgressive familial intrahepatic cholestasisOrphan medicinal productsOrphan drug designationBreakthrough therapy

Mirum Pharmaceuticals LIVMARLI Data Showcased at ESPGHAN Annual Meeting | Region

FOSTER CITY, Calif. (BUSINESS WIRE) May 18, 2024

United statesUnited kingdomCity ofFoster cityLorenzo dantigaIntrahepatic cholestasisJolan terner rosenthalErin murphyRichardj thompsonAndrew mckibbenEuropean commissionKing college londonKing collegeLiver healthDrug administrationMirum pharmaceuticals inc

Mirum Pharmaceuticals LIVMARLI Data Showcased at ESPGHAN Annual Meeting

- Seven abstracts highlighting ALGS and PFIC data, including three oral presentations - Long-term extension data from Phase 3 MARCH-ON PFIC study presented at plenary session and selected among the.

United statesUnited kingdomFoster cityCity ofLorenzo dantigaJolan terner rosenthalRichardj thompsonIntrahepatic cholestasisLiver healthDrug administrationEuropean society for paediatricKing college londonEuropean commissionMirum pharmaceuticals incHealth canadaKing college

Mirum Pharmaceuticals LIVMARLI Receives Positive Reimbursement Recommendation by Canada s CADTH for Patients with Cholestatic Pruritusin Alagille Syndrome

FOSTER CITY - Mirum Pharmaceuticals, Inc. today announced that the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee has recommended public reimbursement for.

Andrew mckibbenBinita kamathChris peetzErin murphyIntrahepatic cholestasisRoberta smithTechnologies in healthAlagille syndrome allianceHealth canadaMirum pharmaceuticals incCanadian agency for drugsEuropean commissionDrug administrationHepatology programExchange commissionCanadian drug expert committee

Mirum Pharmaceuticals LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome -April 02, 2024 at 08:38 am EDT

- Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with this rare liver disorder - LIVMARLI is the first and only.

Binita kamathChris peetzRoberta smithIntrahepatic cholestasisDrug administrationAlagille syndrome allianceHealth canadaCanadian agency for drugsMirum pharmaceuticals incTechnologies in healthCanadian drug expert committeeHepatology programEuropean commissionMirum pharmaceuticalsCanadian agencyAlagille syndrome